If you're in the mood for some summer reading, the July-August edition of "HCV Next" is available online over at Healio.com.
"HCV Next" offers information on a range of topics, which include diagnosis, new combination therapies, side effects, drug/drug interaction, guidelines, fatty liver disease and more.
Millennials, Drugs and HCV
Editorial
A surge in injection drug use is shifting the epidemiology of HCV. In recent years, the number of new cases of hepatitis C virus among people younger than 30 years has increased at an alarming rate. A shift in patterns of injection drug use appears to be driving the changes in HCV epidemiology.
The upsurge in new cases has been observed in US states including Alabama, Colorado, Connecticut, Georgia, Indiana, Massachusetts, New York and West Virginia, among others. HCV infection among injection drug users is increasingly reported in suburban and rural settings, whereas, traditionally, infection has largely been concentrated in urban areas, according to data from Morbidity & Mortality Weekly Report.....
HCV and HIV: Different Viruses, Striking Similarities
The Patient with NAFLD and Chronic HCV
Liver Cancer, Hepatitis Mortality Rates Climbed in US in Past 30 Years
IDSA, HIVMA Voice Support for Syringe Exchange Programs
Alcohol Consumption May Increase Risk for Liver Fibrosis in Coinfected Patients
Benefit of HCC Screening Uncertain for Patients with Chronic Liver Disease
PEDS C: Patients Maintained Long-Term SVR after Pegylated Interferon, Ribavirin
CMS to Cover HCV Screening for High-Risk Adults
FDA Lifts Clinical Hold on Sovaprevir; Phase 2 Trials Move Forward
PCP Training Program Increased Number of Patients Receiving HCV Treatment
5 Questions
"HCV Next" offers information on a range of topics, which include diagnosis, new combination therapies, side effects, drug/drug interaction, guidelines, fatty liver disease and more.
In This Issue
Millennials, Drugs and HCV
Editorial
A surge in injection drug use is shifting the epidemiology of HCV. In recent years, the number of new cases of hepatitis C virus among people younger than 30 years has increased at an alarming rate. A shift in patterns of injection drug use appears to be driving the changes in HCV epidemiology.
The upsurge in new cases has been observed in US states including Alabama, Colorado, Connecticut, Georgia, Indiana, Massachusetts, New York and West Virginia, among others. HCV infection among injection drug users is increasingly reported in suburban and rural settings, whereas, traditionally, infection has largely been concentrated in urban areas, according to data from Morbidity & Mortality Weekly Report.....
Complex debate on the decision to treat HCV with currently available therapies or wait for more options.
A conversation has developed in the hepatitis C virus community surrounding the necessity of treating certain patients with HCV right away or delaying treatment. In short, there is consensus that some patients require immediate intervention, whereas others can be monitored until further complications occur.
The clinical developments at the patient level include the development of fibrosis or more severe complications of HCV. The nonclinical developments at the market level will come in the form of greatly anticipated FDA approvals of new therapies that are currently moving through the pipeline. However, the nuances of the “treat-or-wait” discussion can become convoluted and warrant further investigation....
A conversation has developed in the hepatitis C virus community surrounding the necessity of treating certain patients with HCV right away or delaying treatment. In short, there is consensus that some patients require immediate intervention, whereas others can be monitored until further complications occur.
The clinical developments at the patient level include the development of fibrosis or more severe complications of HCV. The nonclinical developments at the market level will come in the form of greatly anticipated FDA approvals of new therapies that are currently moving through the pipeline. However, the nuances of the “treat-or-wait” discussion can become convoluted and warrant further investigation....
HCV and HIV: Different Viruses, Striking Similarities
The Patient with NAFLD and Chronic HCV
Liver Cancer, Hepatitis Mortality Rates Climbed in US in Past 30 Years
IDSA, HIVMA Voice Support for Syringe Exchange Programs
Alcohol Consumption May Increase Risk for Liver Fibrosis in Coinfected Patients
Benefit of HCC Screening Uncertain for Patients with Chronic Liver Disease
PEDS C: Patients Maintained Long-Term SVR after Pegylated Interferon, Ribavirin
CMS to Cover HCV Screening for High-Risk Adults
FDA Lifts Clinical Hold on Sovaprevir; Phase 2 Trials Move Forward
PCP Training Program Increased Number of Patients Receiving HCV Treatment
5 Questions
So glad you are back. I practically went in to hep C news-withdrawal in your absence. Hope you had a wonderful trip.
ReplyDeleteThank you, had a lovely time. Life is grand!
ReplyDelete